Antidepressant Not Working? 3 Patterns to Check Before You Switch

Feeling like your antidepressant is not working does not always mean the antidepressant is not working.

That sentence is not meant to dismiss what you are experiencing. If you are three months into treatment and still feel the way you felt before you started, something is wrong and it deserves clinical attention. The question is whether what is wrong is the medication itself, or one of several other factors that look like medication failure but have different solutions.

Switching medications prematurely is one of the most consequential errors in psychiatric treatment. The STAR*D trial documented that remission rates decline significantly with each successive antidepressant trial: approximately 37% in the first step, with substantially lower rates at each subsequent step. Every unnecessary cycle through starting and stopping reduces the probability that the next attempt will succeed. Before attributing treatment failure to the medication, three patterns are worth ruling out.

Pattern 1: The Trial Was Not Adequate

The most common reason a psychiatrist looks at a patient's medication history and concludes the "failed" trial was not actually a fair test of the medication is inadequate duration. SSRIs and SNRIs require four to eight weeks at therapeutic doses to produce full antidepressant effect, and some patients require up to 12 weeks for maximum benefit.

This window matters because the neurobiological changes that antidepressants drive, the receptor sensitivity adjustments, the downstream signaling shifts, the structural changes in brain circuitry associated with recovery from depression, do not complete on a faster timeline. As noted in the American Journal of Psychiatry, an adequate trial is generally defined as at least six to eight weeks at an appropriate dose. Stopping at week four because you do not feel better is not a failed antidepressant trial. It is a trial that was never completed.

The early weeks are the hardest. Side effects are most prominent before clinical benefit has developed. Nausea, sleep disruption, activation, and in some cases a brief early increase in anxiety are common and in most cases transient. Stopping in response to these experiences, which is rational in the absence of clinical context, closes the trial before the window for response has opened.

Ask yourself: How long was I on this medication at the current dose before concluding it was not working? If the answer is less than six to eight weeks, the trial may not have been adequate to determine efficacy.

Pattern 2: The Dose Was Never Therapeutic

Prescribers typically start antidepressants at the lowest effective dose to reduce side effects. This is clinically appropriate. What is less appropriate is leaving patients at the starting dose if their response is incomplete.

Standard SSRI starting doses are often below the therapeutic range for depression. Sertraline is commonly initiated at 50 mg, but evidence supports doses of 100-200 mg for full antidepressant effect in many patients. Escitalopram may be started at 5-10 mg when 20 mg produces a stronger clinical response. A patient who has been on the starting dose for six months and reports incomplete response may not have a medication problem. They may have a dosing problem.

Partial response is a specific clinical signal: some improvement but not enough. Partial response argues for dose optimization before switching medications. The AJP review of SSRI discontinuation management notes that dose optimization, including increasing to the maximum tolerated dose before concluding the medication has failed, is a standard clinical step before considering switching.

Ask yourself: Has my prescriber ever increased my dose, and did I feel better when they did? Has the dose been the same since the beginning, without discussion of whether it might be too low? If you have been on the same starting dose throughout and have not experienced clear benefit, the dose is worth discussing before the medication itself is abandoned.

Pattern 3: Something Else Is Driving the Symptoms

SSRIs and SNRIs are effective treatments for major depressive disorder and anxiety. They are not effective for everything that looks like major depressive disorder and anxiety.

Several conditions can present with depressive symptoms and do not respond well to standard antidepressant monotherapy:

• Bipolar depression. Depressive episodes in bipolar disorder often do not respond to antidepressants alone, and in some cases antidepressants can worsen mood cycling. If your depression is accompanied by periods of elevated mood, decreased sleep need, impulsivity, or grandiosity, a bipolar spectrum presentation warrants evaluation before continuing with SSRI monotherapy.
• Medical contributors. Hypothyroidism, vitamin B12 deficiency, sleep apnea, and chronic pain conditions can all produce symptoms that overlap significantly with depression. NIMH clinical guidance notes that medical conditions are routinely assessed when evaluating treatment-resistant depression. If these contributors are present and unaddressed, antidepressants alone are unlikely to produce full remission.
• Inadequately treated anxiety comorbidity. Anxiety and depression frequently co-occur, and anxiety can persist independently even when depressive symptoms improve. If the primary experience is anxiety-driven, the antidepressant dose or choice may need to be calibrated specifically for anxiety rather than depression.
• Substance use. Alcohol use in particular interferes significantly with antidepressant efficacy. Alcohol is a CNS depressant, and regular use can undermine the neurobiological changes that antidepressants are driving.

When Switching Is Actually Indicated

Switching antidepressants is clinically appropriate under several specific conditions: complete non-response after an adequate trial at a therapeutic dose, intolerable side effects that persist beyond the acute phase, or a clinical indication that a different mechanism of action is more appropriate for your presentation.

When switching is appropriate, the method matters. The AJP review describes three switch strategies: direct switch, cross-taper, and taper and switch, with the choice depending on the medications involved, the patient's current dose and clinical stability, and the risk of interaction or discontinuation symptoms. Abrupt discontinuation of an SSRI without a supervised taper can produce significant discontinuation syndrome.

Never stop or change your antidepressant without medical guidance, regardless of how confident you feel that the medication is not working.

Augmentation: The Often-Skipped Middle Step

Between continuing a current medication and switching to a different one is a clinical option that is often skipped in routine care: augmentation, adding a second medication to enhance the response to the first.

Augmentation is particularly appropriate when there has been a partial response to the current antidepressant. A medication that is producing some benefit but not full remission may respond to the addition of a complementary agent rather than requiring replacement.

FDA-approved augmentation strategies for major depressive disorder include the addition of atypical antipsychotics, specifically aripiprazole, brexpiprazole, and quetiapine extended-release, each with clinical trial evidence supporting their use as adjuncts to antidepressant monotherapy. Lithium augmentation has one of the longest evidence histories in psychiatric treatment and remains a recommended option. Bupropion added to an SSRI addresses dopamine and norepinephrine pathways not covered by serotonergic antidepressants alone.

When Your Medication Worked Before but Stopped

A separate clinical pattern from inadequate trial or underdosing is antidepressant tachyphylaxis: a medication that worked initially but has lost effectiveness over time.

Research on antidepressant tachyphylaxis in patients on longer-term treatment has estimated that between 9% and 33% of people on ongoing antidepressant therapy may experience some degree of tolerance or reduced effect over time. Sometimes informally called "Prozac poop-out," tachyphylaxis reflects the brain's adaptation to sustained pharmacological input rather than a fundamental change in the disorder being treated.

Tachyphylaxis is different from treatment resistance. In treatment resistance, the medication never fully worked. In tachyphylaxis, it worked and then stopped. The clinical approach differs accordingly: dose adjustment, brief drug holiday under supervision, switching to a different mechanism, or augmentation may all be appropriate depending on the specific presentation.

How SiggyMD Approaches Treatment Non-Response

When a patient's check-in data shows a pattern that suggests suboptimal treatment response, the SiggyMD clinical team does not simply flag it and wait for the next scheduled appointment. The longitudinal data makes the trajectory visible: whether symptoms have been flat since the start of treatment, whether they improved and then plateaued, or whether improvement is present but partial.

Each of those patterns points to a different clinical question. Flat since the start may mean the dose was never therapeutic. Improvement then plateau may mean dose optimization is needed. Partial response may mean augmentation is more appropriate than switching. The data makes those distinctions possible before they are surfaced verbally at a quarterly visit.

"The question I ask before any switching discussion is whether this medication has actually had a fair trial," says Daniel Montville, MD, of the SiggyMD clinical team. "Were they on it long enough, at the right dose, without adherence gaps? In practice, most patients who come to me describing failed antidepressants have never had an adequate trial of any of them. That is a structural problem with how their care was delivered, not a biological problem with their depression. Fixing the monitoring structure fixes most of the apparent failures."

What Members Are Saying

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Frequently Asked Questions

How Long Should I Give an Antidepressant Before Concluding It Is Not Working?

An adequate antidepressant trial requires four to eight weeks at a therapeutic dose, sometimes up to 12 weeks for full effect. This window reflects the time required for the neurobiological changes antidepressants drive to complete. Stopping at week four because you do not feel better is stopping before the window for response has closed. If your prescriber started you at a low dose and has not increased it, the therapeutic threshold may not have been reached, even if several weeks have passed.

What Does It Mean If I Feel Slightly Better but Not Fully Better on My Antidepressant?

Partial response, meaning some improvement but not full remission, is a specific clinical signal. It typically argues for dose optimization before switching medications. If you are on the starting dose and have experienced improvement without reaching remission, increasing the dose is usually the appropriate next step before concluding the medication has failed. Partial response is also one of the primary indications for augmentation, adding a second medication to enhance the first, which may produce fuller remission than either medication alone.

What Are the Signs That an Antidepressant Is Not Working?

Signs that a medication may genuinely not be working, after an adequate trial at a therapeutic dose, include persistent depression or anxiety at a level similar to before treatment started, no detectable improvement in sleep, energy, or concentration, or symptom improvement in some areas with complete absence of improvement in others. Worsening symptoms on any antidepressant should prompt immediate contact with your prescriber. If you have self-harm or suicidal thoughts, see your doctor immediately, call 911, or go to an emergency room.

What Happens If I Switch Antidepressants Too Many Times?

The STAR*D trial documented that remission rates decline significantly with each successive antidepressant trial, from approximately 37% in the first step to substantially lower rates by the fourth step. Each unsuccessful cycle, particularly cycles that are stopped before adequate trial duration, increases the clinical complexity of subsequent treatment. This is why ruling out inadequate trial, underdosing, and diagnostic issues before switching is clinically important.

What Is Augmentation and When Is It Used?

Augmentation means adding a second medication to an existing antidepressant to enhance its effect. FDA-approved augmentation strategies for major depressive disorder include aripiprazole, brexpiprazole, quetiapine extended-release, lithium, and bupropion added to an SSRI. Augmentation is typically considered when there has been a partial response to the current antidepressant, making the addition of a complementary agent more appropriate than replacement.

Can Medical Conditions Cause Antidepressants to Stop Working?

Yes. Hypothyroidism, vitamin B12 deficiency, sleep apnea, chronic pain, and other medical conditions can produce depressive symptoms or blunt antidepressant response. When standard antidepressant treatment is not producing expected results, evaluating for medical contributors is a standard clinical step before concluding the medication has failed.

Bottom Line

Most cases of apparent antidepressant failure are not failures of the medication. They are failures of the monitoring structure around the medication: trials that ended too early, doses that were never optimized, comorbid conditions that were not evaluated, and the accumulated clinical cost of cycling through medications that were never given a fair test.

Before concluding that your antidepressant is not working, check three things: was the trial adequate, was the dose therapeutic, and is something else contributing to your symptoms. Each of these has a clinical solution that does not require switching to a new medication.

When switching is genuinely indicated, the method and the clinical context matter. A prescriber who has access to your full medication history, your longitudinal symptom trajectory, and your adherence data is making a different quality of decision than one working from your verbal summary of the past year.

Sources

1. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. 2006;163(11):1905-1917.
2. Jha MK, Rush AJ, Trivedi MH. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. American Journal of Psychiatry. 2018;175(12):1176-1184.
3. Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in Clinical Neuroscience. 2015;17(2):111-126.
4. Katz G. Tachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study. Psychiatry and Clinical Neurosciences. 2011;65(5):499-504.
5. Lewis G, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385:1257-1267.
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed May 2026.
7. National Institute of Mental Health. Depression: Overview. NIMH. Accessed May 2026.
8. Rossom RC, et al. Antidepressant adherence across diverse populations and healthcare settings. Depression and Anxiety. 2016;33(8):765-774.